These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 30989487)

  • 21. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.
    Worel N; Fritsch G; Agis H; Böhm A; Engelich G; Leitner GC; Geissler K; Gleixner K; Kalhs P; Buxhofer-Ausch V; Keil F; Kopetzky G; Mayr V; Rabitsch W; Reisner R; Rosskopf K; Ruckser R; Zoghlami C; Zojer N; Greinix HT
    J Clin Apher; 2017 Aug; 32(4):224-234. PubMed ID: 27578390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor.
    Goker H; Etgul S; Buyukasik Y
    Transfus Apher Sci; 2015 Aug; 53(1):23-9. PubMed ID: 26099666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor.
    Bilgin YM; Visser O; Beckers EA; te Boome LC; Huisman C; Ypma PF; Croockewit AJ; Netelenbos T; Kramer EP; de Greef GE
    Transfusion; 2015 May; 55(5):1021-7. PubMed ID: 25641128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis.
    Badar T; Dhakal B; Szabo A; Padmanabhan A; Johnson BD; Heidtke S; Esselmann J; Chhabra S; Hamadani M; Hari P; D'Souza A
    J Clin Apher; 2019 Dec; 34(6):686-691. PubMed ID: 31566813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
    Costa LJ; Kramer C; Hogan KR; Butcher CD; Littleton AL; Shoptaw KB; Kang Y; Stuart RK
    Transfusion; 2012 Nov; 52(11):2375-81. PubMed ID: 22404694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
    Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
    J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of Plerixafor with Granulocyte Colony-Stimulating Factor for Stem Cell Mobilization in a Pediatric Patient.
    Bernardo VA; Ng JS; Joyce MJ
    Ann Pharmacother; 2011 Feb; 45(2):e12. PubMed ID: 21285407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era.
    Johnsrud A; Ladha A; Muffly L; Shiraz P; Goldstein G; Osgood V; Shizuru JA; Johnston L; Arai S; Weng WK; Lowsky R; Rezvani AR; Meyer EH; Frank MJ; Negrin RS; Miklos DB; Sidana S
    Transplant Cell Ther; 2021 Jul; 27(7):590.e1-590.e8. PubMed ID: 33915323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?
    Serin I; Sevindik OG; Balik Aydin B; Melek E; Mutlu YG; Bilgen H; Bekoz H; Kaynar L
    Transfus Apher Sci; 2023 Dec; 62(6):103809. PubMed ID: 37690861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
    Popat U; Saliba R; Thandi R; Hosing C; Qazilbash M; Anderlini P; Shpall E; McMannis J; Körbling M; Alousi A; Andersson B; Nieto Y; Kebriaei P; Khouri I; de Lima M; Weber D; Thomas S; Wang M; Jones R; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):718-23. PubMed ID: 19450756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous Stem Cell Mobilization in the Age of Plerixafor.
    Cooper DL; Medoff E; Patel N; Baker J; Pratt K; Foss F; Seropian SE; Perreault S; Wu Y
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):411-6. PubMed ID: 27245311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
    Sancho JM; Duarte R; Medina L; Querol S; Marín P; Sureda A;
    Med Clin (Barc); 2016 Sep; 147(5):223.e1-223.e7. PubMed ID: 27374031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
    Costa LJ; Alexander ET; Hogan KR; Schaub C; Fouts TV; Stuart RK
    Bone Marrow Transplant; 2011 Jan; 46(1):64-9. PubMed ID: 20383210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plerixafor: a peripheral blood stem cell mobilizer.
    Kessans MR; Gatesman ML; Kockler DR
    Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.
    Selleslag D; Dierickx D; Breems DA; Huynh P; Van De Velde A; Meers S; Brouwer E; Mertens A
    Acta Clin Belg; 2011; 66(3):200-4. PubMed ID: 21837928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
    Mark T; Stern J; Furst JR; Jayabalan D; Zafar F; LaRow A; Pearse RN; Harpel J; Shore T; Schuster MW; Leonard JP; Christos PJ; Coleman M; Niesvizky R
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):795-8. PubMed ID: 18541199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stimulation of adrenergic activity by desipramine enhances hematopoietic stem and progenitor cell mobilization along with G-CSF in multiple myeloma: A pilot study.
    Shastri A; Budhathoki A; Barta SK; Kornblum N; Derman O; Battini R; Raghupathy R; Verma AK; Frenette PS; Braunschweig I; Janakiram M
    Am J Hematol; 2017 Oct; 92(10):1047-1051. PubMed ID: 28675459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
    Tichopád A; Vítová V; Kořístek Z; Lysák D
    J Clin Apher; 2013 Dec; 28(6):395-403. PubMed ID: 23922227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.